ProBio is an outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven trial in patients with metastatic prostate cancer
Joined January 2019
- Tweets91
- Following0
- Followers148
- Likes27
ProBio retweeted
AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j @ProBioTrial
ProBio retweeted
AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j @ProBioTrial
ProBio retweeted
AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j
ProBio retweeted
Don’t forget the @ProBioTrial is an investigator-initiated trial! Crazy level of commitment of everyone involved.
Meet the @ProBioTrial consortium: healthcare professionals from 🇸🇪🇧🇪🇳🇴🇨🇭specialised in the treatment of men with metastatic #ProstateCancer
They made the 🥈#ProBioTrial International Investigator’s Meeting a success 🙏
Presentations soon available on probiotrial.org
ProBio retweeted
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer out on @NatureMedicine
nature.com/articles/s41591-0…
Trial analyzed circulating tumor DNA🧬 and germline DNA in patients randomized to receive androgen receptor pathway inhibitors (ARPIs)💊, taxanes, or physician's choice of treatment🇸🇪
✅The primary endpoint, time to no longer clinically benefitting (NLCB), was met after 218 randomizations. ARPIs showed significantly longer time to NLCB (11.1 months) and overall survival (38.7 months) compared to taxanes and physician's choice treatments.
✅Biomarker analysis revealed that ARPIs were especially effective in AR-negative, TP53 wild-type, and TMPRSS2–ERG fusion-positive patients.
@BramDL
@AlessioCrippa
@sannedhondt
@CelineSchelstr
@LumenNicolaas
@GunillaEnblad1
@cghysel
@wendyderoock
@SiskaVB
@daandm
@jochendarras
@StrijbosMichiel
@jan_oldenburg
@piet_ost
@okelidokeli
Ping: @nataliagandur @bavilima @yekeduz_emre @OncoAlert 🚨
ProBio retweeted
#ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial: AR pathway inhibitors or taxanes for patients with #mCRPC: a direct comparison. Presentation by Henrik Grönberg @karolinskainst. #ESMO23 coverage by @zklaassen_md > bit.ly/3tJOTTD @ProBioTrial
ProBio retweeted
ARPIs or taxanes for pts w/ mCRPC: A direct comparison in 💫ProBio💫, a randomized, outcome-adaptive, biomarker-driven platform trial #ESMO23 @urotoday
📍n=193 randomized to SOC (n=64), taxanes (n=56), ARPIs (n=31)
📍n=77 "re-randomized" to SOC (n=28), taxanes (n=19), ARPIs (n=20)
📍mPFS: 11.1 mo ARPI, 7.4 mo SOC, 6.9 mo taxanes
📍mOS: 38.7 mo ARPI, 21.8 mo SOC, 21.7 mo taxanes
📍 PFS and biomarker signatures 👇
ProBio retweeted
🔵 ProBio Trial Insights: mCRPC Treatment
🔵Biomarker-driven treatment approach for mCRPC.
🔵 Directly randomized data reveal ARPi’s significant superiority in both PFS and OS over other treatments in mCRPC scenario.
@myESMO @OncoAlert #ESMO23 @OncBrothers @urotoday @Uromigos @urologysummit @Silke_Gillessen @neerajaiims @Tilki_De @TiansterZhang @DrChoueiri @montypal @PGrivasMDPhD @drenriquegrande @ChrisSweens1 @DrRanaMcKay @ravikanesvaran @yekeduz_emre @amerseburger @alshamsi2000 @mishabeltran @Ecastromarcos @EfstathiouEleni @APCCC_Lugano
ProBio retweeted
📣Exciting #MedOnc #urology news!
Join us at #ESMO23 for the first @ProBioTrial #Clinicaltrial results 👀
🗓️22.10.2023
⏰09:15
📍Granada Auditorium - Hall 3
📈 Using 🩸🧬 liquid biopsy for AR pathway inhibitors vs. taxanes in metastatic castration-resistant #ProstateCancer
ProBio retweeted
Finally! The @ProBioTrial assay developed by my team @karolinskainst and @scilifelab is finally implemented as a routine diagnostic test @KarolinskaUnsju .
news.ki.se/from-lab-to-hospi…
ProBio retweeted
@ProBioTrial investigator meeting kicking off! 2 days of science, brainstorming and collaboration.
ProBio retweeted
#BMUC22 kicks off with an interactive trial meeting discussing investigator initiated GU cancer trials! Goal: inspiring each other to collaborate! Starting with @ProBioTrial with H. Grönberg and @BramDL
ProBio retweeted
Delighted to share our recent publication: Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant #ProstateCancer mdpi.com/1053174 via @Cancers_MDPI
[1/8]
ProBio retweeted
The @ProBioTrial will expand to the mCSPC setting. In the experimental arm, patients will receive a treatment based on the mutational ctDNA profile. @okelidokeli @BramDL – at Ghent, Belgium
ProBio retweeted
Great questions from Henrik Grönberg on #PROfound trial: why the nonsensical controll arm and where are the QOL data? Great Shout-out to #PROBIOtrial ! @piet_ost @BramDL
ProBio retweeted
First 2 Belgian patients included @uzgent in the @ProBioTrial, an adaptive multi-arm randomized biomarker driven phase 3 trial in men with #mCRPC. Supported by @KOTKanker. Opening more centers across Belgium in upcoming months. @BramDL @okelidokeli